Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31351354 | 0.83 | KMT2A (1.00) | KDM4EKMT2AL3MBTL1GAALMNA | |
| SCHEMBL12125175 | 0.81 | KMT2A (0.76) | KDM4EKMT2AL3MBTL1TSHRALDH1A1 | |
| SCHEMBL1866451 | 0.80 | KMT2A (0.45) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL1864525 | 0.80 | LMNA (0.46) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL10027968 | 0.80 | KMT2A (0.77) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL10027963 | 0.79 | LMNA (0.47) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL10027955 | 0.78 | KMT2A (0.80) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL10027969 | 0.78 | KDM4E (0.70) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL14030918 | 0.78 | KMT2A (0.54) | KDM4EKMT2AL3MBTL1TSHRGAA | |
| SCHEMBL825597 | 0.76 | KMT2A (0.67) | KDM4EKMT2AL3MBTL1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021357-A1 | POSITIVE-TYPE PHOTOSENSITIVE INSULATING RESIN COMPOSITION, AND PATTERN FORMING METHOD USING SAME | NEC CORPORATION (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7939241-B2 | (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20090068587-A1 | (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068587-A1 | (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | MMAB, DNMT3A, MAT1A | KDM4E 1677/4885KMT2A 185/4885L3MBTL1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.